The publication in PLOS ONE shows that NAV-001 has robust single-dose efficacy against multiple mesothelin-expressing cancers and that tumor-produced Humoral Immunology-Oncology (HIO) factors ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback